Keeping it in the family pays dividends (PME)
Novasecta, was recently quoted extensively in an article in Pharmaceutical Market Europe discussing the advantages of being a family- or foundation-controlled pharmaceutical company. Historically a strong focus area, Novasecta has seen first-hand how family- aednd foundation-controlled companies can leverage their unique position by focusing on long-term strategies that often translate into success. The article can be read here, […]
Sanofi CEO hopes for positive results (Scrip)
John Rountree, Managing Partner at Novaescta, was asked by Scrip to comment on Sanofi’s recently reported on-target Q4 results and their outlook for the future. While these results likely reassured investors and analysts that their strategic plan is on track, the real test for Sanofi is yet to come, with multiple critical catalysts expected in […]
GSK’s prospects (CNBC)
Pharma outlook 2017 (CNBC)
J&J and Actelion point to the industry’s future (CNBC, Scrip)
The recent J&J-Actelion deal is great for the pharmaceutical industry, reminding us all of how valuable the capabilities to continuously convert drug discovery activities into fantastic medicines really are. As well as appearing on CNBC on the morning of the deal (video below) to explain this perspective, John Rountree was extensively quoted in Scrip’s analysis of the J&J/Actelion deal. John described […]
Recruitment in UK pharma sector harder post-Brexit (Daily Telegraph)
John Rountree, Managing Partner at Novasecta, was today asked to provide commentary in an article in The Telegraph on the challenges of recruitment in the pharmaceutical sector following the UK’s vote to leave the European Union. John stated that “we’ve been hearing quite a lot of anecdotal evidence that [pharmaceutical executives are] not so much worried […]
Actelion exploring strategic transaction (Bloomberg)
Novasecta’s Managing Partner, John Rountree was asked by Bloomberg to comment on the most recent development for Actelion, that it “has entered into exclusive negotiations with Johnson & Johnson regarding a possible strategic transaction”. He said that J&J, of all the big pharmas, is the best one for Actelion, as it would give the Swiss company […]
Pfizer fined for price hike (Daily Telegraph)
It was recently reported that pharmaceutical companies Pfizer and Flynn Pharma may face a damages claim from the NHS related to overcharging, following their fine for substantially increasing the price of phenytoin sodium capsules. In a front page story in the Business section of the Daily Telegraph on this matter, John Rountree, Managing Partner at […]
Sweden vies for the EMA post-Brexit (Daily Telegraph)
The Telegraph has put out an article reporting that Sweden is vying to be the home of the European Medicines Agency (EMA), currently headquartered in London’s Canary Wharf, once the United Kingdom leaves the European Union. John Rountree, Managing Partner of Novasecta, commented in the article that “if Britain really does leave the EU, the […]
Increased UK funding for science and tech (Reuters)
It was recently announced that, to make up for the loss of EU funding for R&D post-Brexit, Theresa May has pledged to increase the UK’s investment in science and technology by £2 billion per year by 2020. In an article in Reuters, Novasecta, said that it is only a “small step” towards calming Brexit nerves in the […]